Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
By S. Yano, Wei Wang, Qi Li, Kunio Matsumoto, Haruko Sakurama, Takahiro J. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka and 5 more. Cancer Research, 2008
647 citations recorded by the source corpus.
Subfields: Hepatology, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/e3fd5056e41b242641e3e30a1bac1b655c05ffa0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Carlos L. Arteaga
- William Pao
- Vincent A. Miller
- Marc Ladanyi
- Gregory Riely
- P. Jänne
- M. Kris
- J. Engelman
In Pulmonary and Respiratory Medicine
- William Pao
- Carlos L. Arteaga
- J. Engelman
- Gregory Riely
- Vincent A. Miller
- P. Jänne
- M. Kris
- Marc Ladanyi
Citations in the corpus
- EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. (2013, methodology): “RNA interference Duplexed Stealth RNAi (Invitrogen) against BIM and Stealth RNAi-negative control low GC Duplex #3 (Invitrogen) were used for RNA interference (RNAi) assays as described (4).”
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012, background): “Studies from other oncogene addiction paradigms suggest that activation of alternative RTKs can lead to resistance to kinase inhibitors (19, 29, 30).”
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers (2013, background): “Our analysis did not encompass alterations in autocrine or paracrine growth pathways that may also confer resistance (35, 36).”
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC (2010, background): “Additionally, a recent study suggested that the MET ligand, HGF, can promote short-term resistance in two EGFR mutated cancer cell lines (Yano et al., 2008).”
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “Activation ofMET by its ligand hepatic growth factor (HGF) was also sufficient to promote resistance through activation of downstream signaling (Yano et al., 2008).”